Recent studies found the anti-HIV drug efavirenz activated CYP46A1 at the low dose, which could be a new anti-AD treatment (Mast et al., 2017; Mast et al., 2020; van Lier, 2020). This evidence concerns the gene CYP46A1 and Alzheimer disease.